Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
2006 1
2009 2
2013 1
2015 1
2017 1
2019 2
2020 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Innovation in oncology clinical trial design.
Verweij J, Hendriks HR, Zwierzina H; Cancer Drug Development Forum. Verweij J, et al. Cancer Treat Rev. 2019 Mar;74:15-20. doi: 10.1016/j.ctrv.2019.01.001. Epub 2019 Jan 4. Cancer Treat Rev. 2019. PMID: 30665053 Review.
Beyond Randomized Clinical Trials: Use of External Controls.
Schmidli H, Häring DA, Thomas M, Cassidy A, Weber S, Bretz F. Schmidli H, et al. Clin Pharmacol Ther. 2020 Apr;107(4):806-816. doi: 10.1002/cpt.1723. Epub 2019 Dec 17. Clin Pharmacol Ther. 2020. PMID: 31725899 Review.
Rollin Thomas Chamberlin 1881-1948.
Bretz JH. Bretz JH. Science. 1948 Jul 16;108(2794):50-1. doi: 10.1126/science.108.2794.50. Science. 1948. PMID: 17777508 No abstract available.
An integrated biophysical approach to discovering mechanisms of NDM-1 inhibition for several thiol-containing drugs.
Fullington S, Cheng Z, Thomas C, Miller C, Yang K, Ju LC, Bergstrom A, Shurina BA, Bretz SL, Page RC, Tierney DL, Crowder MW. Fullington S, et al. J Biol Inorg Chem. 2020 Aug;25(5):717-727. doi: 10.1007/s00775-020-01794-z. Epub 2020 Jun 4. J Biol Inorg Chem. 2020. PMID: 32500360 Free PMC article.
Recent efforts have been focused on developing inhibitors to these enzymes. In an effort to understand the mechanism of inhibition(s) of four FDA-approved thiol-containing drugs that were previously reported to be inhibitors of New Delhi metallo-beta-lactamase (NDM-1), var …
Recent efforts have been focused on developing inhibitors to these enzymes. In an effort to understand the mechanism of inhibition(s) …
Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
Thomas N. Thomas N. J Biopharm Stat. 2006;16(5):657-77. doi: 10.1080/10543400600860469. J Biopharm Stat. 2006. PMID: 17037264
The model will be evaluated following a strategy proposed by Bretz et al. (2005). The sigmoid Emax model is used to create several contrasts that have high power to detect an increasing trend from placebo. ...
The model will be evaluated following a strategy proposed by Bretz et al. (2005). The sigmoid Emax model is used to create several co …
Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).
Musuamba FT, Manolis E, Holford N, Cheung S, Friberg LE, Ogungbenro K, Posch M, Yates J, Berry S, Thomas N, Corriol-Rohou S, Bornkamp B, Bretz F, Hooker AC, Van der Graaf PH, Standing JF, Hay J, Cole S, Gigante V, Karlsson K, Dumortier T, Benda N, Serone F, Das S, Brochot A, Ehmann F, Hemmings R, Rusten IS. Musuamba FT, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):418-429. doi: 10.1002/psp4.12196. Epub 2017 Jul 19. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28722322 Free PMC article.
Dose selection for phase III trials should be informed by well-designed dose-finding studies; however, the specific choice of method(s) will depend on several aspects and it is not possible to recommend a generalized decision tree. ...
Dose selection for phase III trials should be informed by well-designed dose-finding studies; however, the specific choice of method(s
Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15.
Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Aref AA, et al. JAMA Ophthalmol. 2015 Sep;133(9):1022-9. doi: 10.1001/jamaophthalmol.2015.1823. JAMA Ophthalmol. 2015. PMID: 26086920 Free PMC article. Clinical Trial.
A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.
Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research Group. Scott IU, et al. Arch Ophthalmol. 2009 Sep;127(9):1115-28. doi: 10.1001/archophthalmol.2009.233. Arch Ophthalmol. 2009. PMID: 19752420 Free PMC article. Clinical Trial.
A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.
Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group. Ip MS, et al. Arch Ophthalmol. 2009 Sep;127(9):1101-14. doi: 10.1001/archophthalmol.2009.234. Arch Ophthalmol. 2009. PMID: 19752419 Free PMC article. Clinical Trial.